Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JY017
- Development stage
- Phase 1
- Lead developer
- Zhejiang Orient Gene Biotech
- Modality
- Antibody-Based Therapeutics
01
Overview
JY017 is a drug candidate currently in preclinical development by Beijing Oriental Biotech Co., Ltd. (also known as Beijing Dongfang Baitai Biotechnology Co., Ltd.) for the treatment of autoimmune diseases. While the specific mechanism of action has not been publicly disclosed, the developing company specializes in the research and development of biologics, including monoclonal antibodies, humanized monoclonal antibodies, bispecific antibodies, and antibody fusion proteins. Therefore, JY017 is likely a biologic, potentially an antibody-based therapy, aimed at modulating immune responses implicated in autoimmune conditions.
- Other names
- CD123+CLL-1 dual-target CAR-T cellsCD123/CLL-1 CAR-T
02
Targets
IL3RA (Interleukin 3 Receptor)CLEC12A
Beyond the preview
Go deeper on JY017.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JY017.